Nanjing IASO Bio dosed the first patient in a China Phase I/II trial of its fully human CD19/CD22 CAR-T cell therapy. The trial will enroll patients with CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma. IASO said the candidate is the first fully human dual-targeted CAR-T cell therapy approved to start clinical trials. IASO plans to start a second trial of the CD19/CD22 CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia soon. More details.... Share this with colleagues: // //